Estrogen Metabolite 2-Methoxyestradiol Induces Apoptosis and Inhibits Cell Proliferation and Collagen Production in Rat and Human Leiomyoma Cells: A Potential Medicinal Treatment for Uterine Fibroids

Abstract

Objective: The current study sought to investigate the effect of the estrogen metabolite 2-methoxyestradiol (2-MeOHE₂) on apoptosis, cell proliferation, and collagen synthesis in human and rat leiomyoma cells.

Methods: [³H] thymidine and [³H] proline incorporation studies were conducted. The expression of vascular endothelial growth factor (VEGF), cyclin D1, Bcl-2, and Bax were evaluated by Western blot. Flow cytometry analysis was used to study the effect of 2-MeOHE₂ on apoptosis and the cell cycle.

Results: Compared with untreated controls, treatment of rat leiomyoma (ELT3) cells with 2-MeOHE₂ (0.1, 1, 2, 5, or 10 μM) reduced cell proliferation by 17%, 52%, 61%, 73%, and 79%, respectively (P <.05). Similarly, in human uterine leiomyoma cell line (huLM) cells, proliferation was reduced by 4%, 18%, 37%, 41%, and 51%, respectively. 2-MeOHE₂ also caused a concentration-dependent inhibition of collagen synthesis by 4%, 16%, 23%, 51%, and 70%, respectively, in huLM cells (P <.05). Cell cycle analysis indicated that 2-MeOHE₂ treatment (1 to 5 μM) in huLM cells resulted in G₂/M cell cycle arrest and a 45% increase in apoptosis compared with untreated control (P <.05). Western immunoblotting analysis indicated that 2-MeOHE₂ induces a concentration-dependent reduction in the expression of cyclin D1, Bcl-2, and VEGF proteins in both rat and human leiomyoma cell lines.

Conclusions: This study provides the first evidence that 2-MeOHE₂ is a potent antiproliferative/apoptotic and collagen synthesis inhibiting agent in human and rat leiomyoma cells. To the best of our knowledge, this is the first report showing the potential use of 2-methoxyestradiol as a nonsurgical alternative therapy for uterine leiomyomas.

Keywords

2-Methoxyestradiol uterine leiomyoma apoptosis collagen synthesis cell cycle

Get full access to this article

View all access options for this article.

References

1. Al-Hendy A , Lee EJ , Wang HQ , Copland JA . Gene therapy of uterine leiomyomas: Adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol 2004;191:1621-1631.

2. Walker CL , Stewart EA . Uterine fibroids: The elephant in the room. Science 2005;308:1589-1592.

3. Cook JD , Davis BJ , Cai SL , et al. Interaction between genetic susceptibility and early-life environmental exposure determines tumor-suppressor-gene penetrance. Proc Natl Acad Sci U S A 2005;102:8644-8649.

4. Maruo T , Ohara N , Wang J , Matsuo H . Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 2004;10:207-220.

5. Cook JD , Walker CL . Treatment strategies for uterine leiomyoma: The role of hormonal modulation. Semin Reprod Med 2004;22:105-111.

6. Martel KM , Ko AC , Christman GM , Stribley JM . Apoptosis in human uterine leiomyomas. Semin Reprod Med 2004;22:91-103.

7. Strober S , Lowsky RJ , Shizuru JA , Scandling JD , Millan MT . Approaches to transplantation tolerance in humans. Transplantation 2004;77:932-936.

8. Ishwad CS , Ferrell RE , Davare J , et al. Molecular and cytogenetic analysis of chromosome 7 in uterine leiomyomas. Genes Chromosomes Cancer 1995;14:51-55.

9. Bodner K , Bodner-Adler B , Kimberger O , Czerwenka K , Mayerhofer K . Bcl-2 receptor expression in patients with uterine smooth muscle tumors: An immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. J Soc Gynecol Investig 2004;11:187-191.

10.

10. Matsuo H . Molecular bases for the actions of ovarian sex steroids in the regulation of proliferation and apoptosis of human uterine leiomyoma. Oncology 1999;57:49-58.

11.

11. Zhao J , Dorland M , Taverne MA , et al. In vitro culture of rat pre-antral follicles with emphasis on follicular interactions. Mol Reprod Dev 2000;55:65-74.

12.

12. Kawaguchi K , Fujii S , konishi I , Okamura H , Mori T . Ultrastructural study of cultured smooth muscle cells from uterine leiomyoma and myometrium under the influence of sex steroids. Gynecol Oncol 1985;21:32-41.

13.

13. Stewart EA , Friedman AJ , Peck K , Nowak RA . Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab 1994;79:900-906.

14.

14. Zhu BT , Conney AH . Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998;58:2269-2277.

15.

15. Lis A , Ciesielski MJ , Barone TA , et al. 2-Methoxyestradiol inhibits proliferation of normal and neoplastic glial cells, and induces cell death, in vitro. Cancer Lett 2004;213:57-65.

16.

16. Joubert A , Maritz C , Joubert F . Bax/Bcl-2 exression levels of 2-methoxyestradiol-exposed esophageal cancer cells. Biomed Res 2005;26:131-134.

17.

17. Chamon K , Stojek J , Kanakis D , et al. Micromolar concentrations of 2-methoxyestradiol kill glioma cells by an apoptotic mechanism, without destroying their microtubule cytoskeleton. J Neurooncol 2005;72:11-16.

18.

18. Bu SZ , Huang Q , Jiang YM , et al. p38 Mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2. Apoptosis 2006;11:413-425.

19.

19. Zacharia LC , Gogos JA , Karayiorgou M , et al. Methoxyestradiols mediate the antimitogenic effects of 17beta-estradiol: Direct evidence from catechol-O-methyltransferase-knockout mice. Circulation 2003;108:2974-2978.

20.

20. Banerjee SN , Sengupta K , Banerjee S , Saxena NK , Banerjee SK . 2-Methoxyestradiol exhibits a biphasic effect on VEGF-A in tumor cells and upregulation is mediated through ER-alpha: A possible signaling pathway associated with the impact of 2-ME2 on proliferative cells. Neoplasia 2003;5:417-426.

21.

21. Dubey RK , Jackson EK , Gillespie DG , et al. Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. Arterioscler Thromb Vasc Biol 2000;20:964-972.

22.

22. Mooberry SL . New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 2003;15:425-430.

23.

23. Lakhani NJ , Sarkar MA , Venitz J , Figg WD . 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 2003;23:165-172.

24.

24. Sweeney C , Liu G , Yiannoutsos C , et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 2005;11:6625-6633.

25.

25. Howe SR , Gottardis MM , Everitt JI , et al. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol 1995;146:1568-1579.

26.

26. Rauk PN , Surti U , Roberts JM , Michalopoulos, G . Mitogenic effect of basic fibroblast growth factor and estradiol on cultured human myometrial and leiomyoma cells. Am J Obstet Gynecol 1995;173:571-577.

27.

27. Swartz CD , Afshari CA , Yu L , Hall KE , Dixon D . Estrogen-induced changes in IGF-I, Myb family and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines. Mol Hum Reprod 2005;11:441-450.

28.

28. Teare JM , Islam R , Flanagan R , et al. Measurement of nucleic acid concentrations using the DyNA Quant and the GeneQuant. Biotechniques 1997;22:1170-1174.

29.

29. Telford WG , King LE , Fraker PJ . Rapid quantitation of apoptosis in pure and heterogeneous cell population using flow cytometry. J Immunol Methods 1994;172:1-16.

30.

30. Vijayanathan V , Venkiteswaran S , Nair SK , et al. Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in human breast cancer cells. Clin Cancer Res 2006;12:2038-2048.

31.

31. Schumacher G , Neuhaus P . [2-Methoxyestradiol—A new compound for cancer treatment]. Dtsch Med Wochenschr 2006;131:825-830.

32.

32. Figg WD , Kruger EA , Price DK , Kim S , Dahut WD . Inhibition of angiogenesis: Treatment options for patients with metastatic prostate cancer. Invest New Drugs 2002;20:183-194.

33.

33. Mabjeesh NJ , Escuin D , LaVallee TM , et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-375.

34.

34. Gokmen-Polar Y , Escuin D , Walls CD , et al. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res 2005;65:9406-9414.

35.

35. Qadan LR , Perez-Stable CM , Anderson C , et al. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cance. Biochem Biophys Res Commun 2001;285:1259-1266.

36.

36. Barchiesi F , Jackson EK , Gillespie DG , et al. Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs. Hypertension 2002;39:874-879.

37.

37. Lewis JS , Thomas YJ , Pestell RG , et al. Differential effects of 16alpha-hydroxyesterone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells. J Mod Endocrinol 2005;34:91-105.

38.

38. Ghosh R , Ott AM , Seetharam D , Slaga TJ , Kumar AP . Cell cycle block and apoptosis induction in a human melanoma cell line following treatment with 2-methoxyoestradiol: Therapeutic implications? Melanoma Res 2003;13:119-127.

39.

39. Wyllie AH , Kerr JF , Currie AR . Cell death: The significance of apoptosis. Int Rev Cytol 1980;68:251-306.

40.

40. Reed JC , Talwar HS , Cuddy M , et al. Mitochondrial protein p26 BCL2 reduces growth factor requirements of NIH3T3 fibroblasts. Exp Cell Res 1991;195:277-283.

41.

41. Nunez G , London L , Hockenbery D , et al. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990;144:3602-3610.

42.

42. Zhai YL , Nikaido T , Toki T , et al. Prognostic sigificance of bcl-2 expression in leiomyosarcoma of the uterus. Br J Cancer 1999;80:1658-1664.

43.

43. Matsuo H , Maruo T , Samoto T . Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 1997;82:293-299.

44.

44. Khurana KK , Singh SB Tatum AH , Schulz V , Badawy SZ . Maintenance of increased Bcl-2 expression in uterine leiomyomas after GmRH agonist therapy. J Reprod Med 1999;44:487-492.

45.

45. Di Lieto A , De Falco M , Pollio F , et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig 2005;12:123-128.

46.

46. Folkman J , Shing Y . Angiogenesis. J Biol Chem 1992;267:10931-10934.

47.

47. Gentry CC , Okolo SO , Fong LF , et al. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin Sci (Lond) 2001;101:691-695.

48.

48. Chauhan D , Catley L , Hideshima T , et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood 2002;100:2187-2194.

49.

49. Ferenczy A , Richart RM , Okagaki T . A comparative ultrastuctural study of leiomyosarcoma, cellular leiomyoma, and leiomyoma of the uterus. Cancer 1971;28:1004-1018.

50.

50. Purohit A , Tutill HJ , Day JM , et al. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer. Molecular Cell Endocrinology 2006;248:199-203.